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Neuroprotection and repair are two of the biggest unmet therapeutic needs in people 
with progressive MS. Despite recent positive trials of ocrelizumab and saponimod, the 
process of drug discovery for these needs remains painfully slow and difficult. This 
contrasts with the situation in relapsing MS, where there is an efficient pathway for 
discovering drugs to prevent relapse: the effects of candidate drugs on what has 
emerged as the dominant underlying pathology (inflammation) can be assessed with 
an MRI biomarker (lesion activity), which also correlates with meaningful clinical 
outcome (relapse)
1
.  
 
The situation is more complicated in progressive MS, because there are numerous 
mechanisms which contribute to neurodegeneration
2
, and meaningful disability 
outcomes are still under discussion
3
. Increasingly sophisticated computational and 
phenotypic screens are likely to gene ate drug candidates acting on some of these 
mechanisms, including compartmentalized and innate immunity, energy failure, ionic 
imbalances and aspects of glial biology
2
. Comparison with relapsing MS suggests that 
drug development would be accelerated with rational pipelines that include 
biomarkers which are selected to measure the effects of drugs on specific injury and 
repair mechanisms.  
 
For now, neurodegeneration is generally assessed using MRI techniques to measure 
atrophy, which integrates the end-stage consequences of diverse injury mechanisms.  
However, atrophy is affected by tissue hydration and by a complex interplay between 
volumes in multiple cellular compartments, limiting its sensitivity and responsiveness, 
as well as the interpretation of volume changes shortly after treatment is started. 
Furthermore, neural injury is likely to continue long after its cause is inhibited, 
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leading to a therapeutic lag which could delay any response of atrophy to treatment by 
several years
4
. It remains to be seen whether these issues also place limits on more 
refined techniques for tissue microstructure and cellular integrity such as 
magnetization transfer ratio (MTR) and optical coherence tomography (OCT), which 
are outcomes in repair and progression trials reporting in the intermediate future. 
However, even with further technical refinements, measurements of tissue structure 
alone may not be sufficiently specific to enable shorter and smaller proof of concept 
trials in progressive disease.  
 
Tissue fluid biomarkers for injury mechanisms offer greater pathological specificity, 
and include nitric oxide metabolites, chemokines associated with intrathecal B 
lymphocyte activity, and neurofilaments released by damaged axons. However, 
validation of these biomarkers has p oved difficult, and they usually need to be 
measured in the spinal fluid.  
 
Positron emission tomography (PET) offers highly sensitive and specific information 
about tissue cellularity and metabolism. PET radioligands are available for dissecting 
tissue metabolism, for myelin and neurons
5
, and for activated microglia
6
. Despite its 
attractions for dissecting mechanisms in early stage proof of concept studies, 
however, wider implementation of PET as an outcome in clinical trials, especially 
multicentre studies, is likely to be limited by its expense and restricted availability, 
and by associated practical difficulties for establishing the validity of its outcomes. 
 
OCT techniques are advancing rapidly, and in addition to providing sensitive 
measurements of neuronal and axonal compartments, they have the potential to study 
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aspects of retinal metabolism. Despite correlations with CNS outcomes, however, 
acceptance of OCT outcomes may be limited by the ongoing debate about the extent 
to which results in the visual system can be related to processes in the wider CNS.  
 
These limitations suggest that MRI techniques are likely to provide the most practical 
approach for developing biomarkers for drug pipelines in the intermediate future. The 
main attraction of MRI remains its ability to resolve structure, and MTR and diffusion 
based methods including tractography take this further than conventional imaging. 
However, advanced techniques show promise for differentiating disease mechanisms.  
Diffusion basis spectrum imaging
7
 has the potential to resolve myelin, axons and 
inflammation; high field MRI can detect sub-surface abnormalities potentially driven 
by meningeal pathology
8
; and techniques which examine metabolic events in the 
injury pathway include sodium imaging
9
, cerebral perfusion, and N-acetylaspartate as 
a mitochondrial signal. Functional MRI sits alongside these techniques because it 
offers the possibility of determining whether cerebral networks which are disordered 
by pathology can be renormalized by therapies which have restorative or repair 
potential
10
. Such functional changes would complement improvements in other 
outcomes for testing repair strategies. 
 
Apart from being available widely, MRI also has the advantage of versatility: multiple 
structural, functional and metabolic measurements can be made in single subjects. 
Experience in other conditions including Alzheimer’s disease suggests that 
multimodal imaging may provide a more robust biomarker with which to measure 
disease activity, and combined imaging of the spinal cord in MS using conventional 
and more advanced MRI techniques appears to support this view
11
. 
Page 4 of 7
http://mc.manuscriptcentral.com/multiple-sclerosis
Multiple Sclerosis Journal
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 
For all of these techniques, validation against disability outcomes and responsiveness 
to therapy need much further study. Longitudinal natural history studies are helpful, 
but validation is likely to be achieved more efficiently if selected measures are 
included as outcomes in placebo and treated groups in future clinical trials. Given 
restricted resources and a limited appetite for risk, should preference be given to 
developing techniques based on MRI over others? The distinction may ultimately be 
unhelpful: rather than choosing between MRI and PET, for example, it may be more 
relevant to evaluate the potential of specific techniques to measure the effects of 
treatments based on their ability to address a given mechanism of action, irrespective 
of modality.  
 
In conclusion, this brief overview presents a case for developing rational pipelines for 
drug discovery to meet major unmet needs in progressive MS by validating a number 
of advanced biomarkers which show promise for quantifying specific cellular and 
pathological aspects of neurodegeneration and repair. It seems unlikely that any single 
modality will be sufficient to assess all of the mechanisms which underlie these 
processes, but MRI-based techniques are likely to predominate simply because the 
versatility and availability of MRI compared with other modalities makes it easier to 
implement. 
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